文献速递主动脉疾病

Streamliner多层血流调节器腔内治疗慢性症状性主动脉夹层的全球注册研究12个月结局

Endovascular management of chronic symptomatic aortic dissection with the Streamliner Multilayer Flow Modulator: Twelve-month outcomes from the global registry.
PubMed 文献 · J Vasc Surg · 2017-01-01

OBJECTIVE: Reported are initial 12-month outcomes of patients with chronic symptomatic aortic dissection managed by the Streamliner Multilayer Flow Modulator (SMFM; Cardiatis, Isnes, Belgium).…

要点

  • SMFM治疗慢性症状性主动脉夹层12个月无破裂及主动脉相关死亡。
  • 12个月无神经事件、截瘫、肾衰竭及终末器官缺血发生。

核心结论

  • SMFM是复杂全主动脉夹层的一种治疗选择,可稳定夹层、无动脉瘤进展及逆行A型夹层。
  • SMFM胸主动脉腔内修复实现无主动脉破裂、卒中和截瘫及肾衰竭。

研究设计与样本

  • 全球注册研究,876例SMFM植入中已知542例,312例维持于注册,其中38例(12.2%)为主动脉夹层。
  • 适应证包括35例Stanford B型、2例Stanford A和B型、1例真菌性Stanford B型夹层。

主要发现

  • 无破裂或主动脉相关死亡报告,全因生存率85.3%。
  • 12个月无神经事件 freedom 为100%,无终末器官缺血、截瘫或肾损伤发生。

临床怎么用

  • 对于复杂全主动脉夹层,SMFM植入可作为管理选项,需关注夹层稳定性和无逆行A型夹层。

局限性

  • 需进一步分析全球注册数据以了解长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Reported are initial 12-month outcomes of patients with chronic symptomatic aortic dissection managed by the Streamliner Multilayer Flow Modulator (SMFM; Cardiatis, Isnes, Belgium). Primary end points were freedom from rupture- and aortic-related death, and reduction in false lumen index. Secondary end points were patency of great vessels and visceral branches, and freedom of stroke, paraplegia, and renal failure. METHODS: Out of 876 SMFM implanted globally, we have knowledge of 542. To date, 312 patients are maintained in the global registry, of which 38 patients were identified as having an aortic dissection (12.2%). Indications included 35 Stanford type B dissections, two Stanford type A and B dissections, and one mycotic Stanford type B dissection. RESULTS: There were no reported ruptures or aortic-related deaths. All cause survival was 85.3% Twelve-month freedom from neurologic events was 100%, and there were no incidences of end-organ ischemia, paraplegia or renal insult. Morphologic analysis exhibited dissection remodeling by a reduction in longitudinal length of the dissected aorta, and false lumen volume. A statistically significant reduction in false lumen index (P = .016) at 12 months, and a borderline significant increase in true lumen volume (P = .053) confirmed dissection remodeling. CONCLUSIONS: The SMFM is an option in management of complex pan-aortic dissection. Results highlight SMFM implantation leads to dissection stabilization with no further aneurysm progression, and no retrograde type A dissection. Thoracic endovascular aneurysm repair by SMFM ensued in freedom from aortic rupture, neurologic stroke, paraplegia and renal failure. Further analysis of the global registry data will inform long-term outcomes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Sultan S, Kavanagh EP, Stefanov F, et al. Endovascular management of chronic symptomatic aortic dissection with the Streamliner Multilayer Flow Modulator: Twelve-month outcomes from the global registry. J Vasc Surg. 2017. PMID: 28342521. doi:10.1016/j.jvs.2016.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。